Join to View Full Profile
101 The City Dr SOrange, CA 92868
Phone+1 714-456-8000
Fax+1 714-456-2242
Dr. Nagasaka is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Detroit Medical Center/Wayne State UniversityFellowship, Hematology and Medical Oncology, 2014 - 2017
Icahn School of Medicine at Mount Sinai/Beth IsraelResidency, Internal Medicine, 2011 - 2014
Certifications & Licensure
HI State Medical License 2021 - 2026
CA State Medical License 2021 - 2025
MI State Medical License 2017 - 2024
SC State Medical License 2013 - 2013
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Home Sleep Apnea Machine in Evaluating Obstructive Sleep Apnea in Patients With Stage III-IV Head and Neck Cancer Start of enrollment: 2023 Jul 25
- Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC Start of enrollment: 2021 Sep 01
Roles: Contact
- EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer Start of enrollment: 2023 Jun 01
Roles: Contact
Publications & Presentations
PubMed
- Prevalence and molecular correlates of acquiredresistance mutations in non-small cell lung cancer (NSCLC).Luis E Raez, Yasmine Baca, Jennifer R Ribeiro, Jorge J Nieva, Hirva Mamdani
Expert Review of Anticancer Therapy. 2025-04-17 - Oncogenic gene fusions in cancer: from biology to therapy.Stephen V Liu, Misako Nagasaka, Judith Atz, Flavio Solca, Leonhard Müllauer
Signal Transduction and Targeted Therapy. 2025-04-14 - Taletrectinib in+ Non-Small Cell Lung Cancer: TRUST.Maurice Pérol, Wei Li, Nathan A Pennell, Geoffrey Liu, Yuichiro Ohe
Journal of Clinical Oncology. 2025-04-03
Press Mentions
AnHeart Therapeutics Announces Publication of Taletrectinib Global Phase 2 Clinical Trial (TRUST-II) Design in Future OncologyMarch 9th, 2023- AnHeart Therapeutics to Present Poster and Host Investigator Meeting at WCLC 2022August 4th, 2022
- Dr. Nagasaka Named to National 40 Under 40 in Cancer Class of 2020November 17th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
